Moderna and Mitsubishi Tanabe Pharma have partnered to promote Moderna's mRNA respiratory vaccine portfolio in Japan, including the Covid-19 vaccine, Spikevax. The collaboration aims to enhance public health impact and ensure widespread vaccine access until 2029.